Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of intranasal adenovirus vector vaccine is attenuated by type I IFN-induced NK cell activation.

Molecular therapy. Advances·2026
Same author

STING agonists as next-generation vaccine adjuvants: mechanisms, opportunities, and challenges.

Current opinion in virology·2026
Same author

TANK-binding kinase 1 (TBK1): unexpected cell type-specific immune regulation beyond antiviral type I interferon signaling.

Current opinion in virology·2026
Same author

A poorly reactogenic lipid nanoparticle-mRNA vaccine unveils an innate immune pathway for adverse reactions.

NPJ vaccines·2026
Same author

Human erythropoietin mRNA as an impurity from a mRNA-LNP vaccine induces immune-mediated anemia in rats.

The Journal of toxicological sciences·2026
Same author

cGAS-IFN-I responses by extracting nuclear DNA from dying cells via nucleocytosis.

Nature communications·2026

Related Experiment Video

Updated: Apr 1, 2026

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.4K

IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific manner.

Yuya Yoshioka1,2, Anri Nishinaka-Yoshioka1,2, Kouji Kobiyama2,3

  • 1Vaccine R&D Laboratory, Shionogi & Co. Ltd., Osaka, Japan.

NPJ Vaccines
|March 30, 2026
PubMed
Summary

Squalene adjuvants enhance immune responses via distinct IL-1 pathways. Adjuvant efficacy and reactogenicity are regulated by separate mechanisms involving specific cell types, offering insights for safer vaccine development.

More Related Videos

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
08:15

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

2.4K
In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model
07:05

In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model

Published on: November 28, 2017

10.4K

Related Experiment Videos

Last Updated: Apr 1, 2026

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

9.4K
In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
08:15

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

2.4K
In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model
07:05

In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model

Published on: November 28, 2017

10.4K

Area of Science:

  • Immunology
  • Vaccinology
  • Molecular Biology

Background:

  • Squalene-based adjuvants, like A-910823 and AS03, are crucial for vaccine efficacy.
  • These adjuvants contain α-tocopherol and enhance immune responses, but their mechanisms are not fully understood.
  • Existing knowledge suggests they boost humoral immunity and cytokine production.

Purpose of the Study:

  • To elucidate the mechanisms by which squalene-based adjuvants, specifically A-910823, enhance immune responses.
  • To investigate the role of α-tocopherol in adjuvant-mediated IL-1 signaling.
  • To differentiate the pathways regulating adjuvant efficacy and reactogenicity.

Main Methods:

  • Analysis of IL-1 signaling pathway gene and protein expression.
  • Identification of cell types responsible for IL-1α and IL-1β production.
  • Investigation of key molecular axes (e.g., IL-1β/CD11c+ cell-IL-1R1/MyD88) in adjuvant function and reactogenicity.

Main Results:

  • A-910823 regulates IL-1 signaling and IL-1α/IL-1β expression in an α-tocopherol-dependent manner.
  • IL-1α originates mainly from eosinophils, while IL-1β is produced by various myeloid cells.
  • Adjuvant efficacy is mediated by the IL-1β/CD11c+ cell-IL-1R1/MyD88 axis.
  • Systemic reactogenicity involves the IL-1β/IL-1R1/MyD88/IL-6/cyclooxygenase 2 axis.
  • Local reactogenicity is mediated by the eosinophil-derived IL-1α/IL-1R1/MyD88 axis.

Conclusions:

  • Adjuvant efficacy and reactogenicity are governed by distinct pathways and cell types.
  • The study reveals novel insights into squalene-based adjuvant mechanisms.
  • Findings support the development of safer and more effective vaccines.